[This corrects the article DOI: 10.1016/j.apsb.2021.07.027.]

Batra, Neelu

Deng, Linglong

Petrek, Hannah

Tu, Mei-Juan

Yu, Ai-Ming

Yu, Ai-Xi

eScholarship - University of California

UC DavisUC Davis Previously Published WorksTitleErratum: Author correction to Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965].Permalinkhttps://escholarship.org/uc/item/40w8g551JournalACTA Pharmaceutica Sinica B, 13(8)ISSN2211-3835AuthorsDeng, LinglongPetrek, HannahTu, Mei-Juanet al.Publication Date2023-08-01DOI10.1016/j.apsb.2023.07.002 Peer reviewedeScholarship.org Powered by the California Digital LibraryUniversity of CaliforniaActa Pharmaceutica Sinica B 2023;13(8):3577e3578Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical SciencesActa Pharmaceutica Sinica Bwww.elsevier.com/ loca te /apsbwww.sc iencedi rec t .comCORRECTIONAuthor correction to ‘Bioengineered miR-124-3pprodrug selectively alters the proteome ofhuman carcinoma cells to control multiplecellular components and lung metastasis in vivo’[Acta Pharmaceutica Sinica B 11 (2021)3950e3965]Linglong Denga,b, Hannah Petrekb, Mei-Juan Tub, Neelu Batrab,Ai-Xi Yua,*, Ai-Ming Yub,*aDepartment of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430072,ChinabDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USAThe authors regret that there was one incorrect image used withinFig. 4A, 143B cells treated with LSA at 24 h time point, whichwas obtained from vehicle group but mislabelled as LSA in thepublication. In our studies, three biological replicates wereincluded in each treatment group and at least three images weretaken for different fields of each sample. We thus selected a cor-rect representative image from the LSA treated 143B cells at 24 htime point to replace that mislabelled image, and the updatedDOI of original article: https://doi.org/10.1016/j.apsb.2021.07.027.*Corresponding authors.E-mail addresses: yuaixi@whu.edu.cn (Ai-Xi Yu), aimyu@ucdavis.edu (AiPeer review under the responsibility of Chinese Pharmaceutical Association anhttps://doi.org/10.1016/j.apsb.2023.07.0022211-3835 ª 2023 Chinese Pharmaceutical Association and Institute of Materiby Elsevier B.V. This is an open access article under the CC BY-NC-ND licenFig. 4 is provided below. The authors apologize for any incon-venience caused to the journal and readers, while this correctiondoes not affect any results and conclusions. The authors haveprovided the original data of this figure to Editorial Office, and thecorresponding authors or the Editorial Office can be contacted fororiginal data access.The authors sincerely apologize for any inconvenience causedto the journal and readers.-Ming Yu).d Institute of Materia Medica, Chinese Academy of Medical Sciences.a Medica, Chinese Academy of Medical Sciences. Production and hostingse (http://creativecommons.org/licenses/by-nc-nd/4.0/).3578 Linglong Deng et al.

English

Erratum: Author correction to Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in&nbsp;vivo [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965].

Erratum: Author correction to Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965].

Abstract

Similar works

Full text

Available Versions

eScholarship - University of California

Erratum: Author correction to Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in&nbsp;vivo [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965].

Abstract

Similar works

Full text

Available Versions

eScholarship - University of California

Erratum: Author correction to Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965].